David Clemmons, M.D.

Scientific Advisory Board

Dr. Clemmons is the Sarah Graham Kenan professor of Medicine at the University of North Carolina, Chapel Hill School of Medicine and serves as a scientific and clinical development adviser for growth hormone related diseases. He has been a faculty member in the Division of Endocrinology in the Department of Medicine since December 1979 serving as chief of the Endocrinology Division for 17 years and as director of the Diabetes Center of Excellence for five years. Dr. Clemmons has also served on the Council of the Endocrine Society, in addition to being editor of Endocrinology, Molecular Endocrinology and Endocrine Reviews. One of his main areas of research has been clinical investigation of patients with pituitary diseases. These studies have focused principally on diagnosis and treatment of acromegaly and the therapeutic options for management of patients with growth hormone deficiency and hypopituitarism. He has published over 260 original scientific papers, including 82 that deal directly with diagnosis and management of these diseases. He has conducted several clinical trials and been the lead investigator in three registration trials for products that are available to treat growth hormone deficiency and acromegaly. He has served on multiple scientific advisory boards for biotechnology and major pharmaceutical companies. He has been a member the data safety and monitoring committee for 10 major clinical trials. He is the principle inventor on 17 issued patents and is the scientific founder of three biotechnology companies, including Vascular Pharmaceuticals which is currently conducting a phase 2 human trials for the treatment of diabetic nephropathy.